Bleomycin
DB00290
Approved Indication
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
2
Targets
0
Resistance Mutations
1
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro. It is believed that bleomycin chelates metal ions (primarily iron) producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA.
Details
DrugBank ID
DB00290 ↗
Approval Date
2000-03-10
Molecular Weight
1415.552 g/mol
Drug Class
Other
ATC Codes
L01DC01
Synonyms
Bleocin, Bleomicin, Bleomicina
PubChem
CID: 5360373 ↗
ChEMBL
CHEMBL403664 ↗
SMILES
C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C
ADMET Profile
Computing properties…
Drug References (DrugBank)